{"schema_version":"secwatch.filing_event.v1","accession":"0000021076-23-000013","form_type":"8-K","ticker":"CLX","cik":"0000021076","company_name":"CLOROX CO /DE/","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.666460+00:00","generated_at":"2026-06-16T03:53:13.853988+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clorox Q3 FY2023: adj EPS +15%, net sales +6%, raises full-year outlook","bullets":["Net sales $1.91B (+6% YoY); organic sales +8%; gross margin 41.8% (+590 bps).","Adjusted EPS $1.51 (+15% YoY); GAAP diluted EPS loss $1.71 due to $445M impairment in vitamins.","YTD operating cash flow $728M, up 61% YoY; free cash flow $584M, 10.9% of sales.","Health & Wellness segment volume -16% but price/mix +23%; Lifestyle sales +15%.","Company raises FY2023 outlook citing pricing, cost savings, and strategic investments."],"urls":{"canonical":"https://secwatch.observer/filing/0000021076-23-000013","json":"https://secwatch.observer/filing/0000021076-23-000013.json","markdown":"https://secwatch.observer/filing/0000021076-23-000013.md","text":"https://secwatch.observer/filing/0000021076-23-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/21076/000002107623000013/0000021076-23-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/21076/000002107623000013/clx-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:53:13.853988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9e29711d539c9055cbb9b85dea775e3fd8a5724","claim":"CLOROX CO /DE/ reported third quarter ended March 31, 2023 results: revenue $1.91 billion, EPS (a noncash impairment charge of $445 million ($362 million after tax or $2.92) ...). Guidance raised.","evidence_excerpt":"Summary Following is a summary of key third-quarter results. All comparisons are with the third quarter of fiscal year 2022 unless otherwise stated. • Net sales increased 6% to $1.91 billion compared to a 2% net sales increase in the year-ago quarter. The net sales increase was driven largely by favorable price mix, partially offset by lower volume. Organic sales 1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/21076/000002107623000013/0000021076-23-000013-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended March 31, 2023"},{"label":"Revenue","value":"$1.91 billion"},{"label":"EPS","value":"(a noncash impairment charge of $445 million ($362 million after tax or $2.92) ...)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}